Louisa Lim, NPR
Jena Teague and Terry Williams brought their blind, 7-month-old baby Laylah to China for an experimental stem-cell treatment. Laylah has optic nerve hypoplasia, an incurable condition. Chinese doctors say they see signs her therapy is working.
Other Possible Treatments
Some U.S. experts say there's no evidence that the stem cell therapy being offered in China will work in one of the most common causes of childhood blindness, optic nerve hypoplasia (ONH). Dr. Mark Borchert, head of the vision center at Children's Hospital Los Angeles, weighs in on the debate and possible treatments.
Read that story.
China is gaining popularity among a new breed of travelers: patients with incurable conditions who are visiting the country to receive experimental stem-cell treatments not offered in the United States.
One company is now claiming a medical breakthrough, advertising that its treatments are restoring vision to blind children. It has ignited a firestorm of controversy in both China and in the U.S.
Giving Parents a New Option
Jena Teague and her husband Terry Williams are among these new visitors. They traveled to China to seek stem-cell treatment for their blind, 7-month-old baby daughter, Laylah. She was born with optic nerve hypoplasia, or ONH — when the optic nerves fail to develop properly in the womb. Conventional medicine offers no treatment and no cure.
But Teague came across a Web site about stem-cell treatments offered by Beike Biotechnology in China and decided to try it — against advice from specialists at home in Georgia.
"None of the specialists had heard of the stem cells, of what they're doing here. They didn't believe it would work. They told me not to expect anything to happen out of it," Teague says.
Nonetheless, the family traveled to the eastern Chinese city of Hangzhou, where Beike is based. They are spending $23,000 for Laylah to have infusions of stem cells harvested from umbilical cords — not the more controversial embryonic stem cells. In the U.S., cord blood stem cells are used for treating blood diseases, but are not used for treating other conditions, such as Laylah's vision problem.
Treatment Seems to Yield Positive Results
After three sessions, Teague and Williams say the therapy is already working.
The doctors have told Laylah's parents that the baby now sees light through one eye, while the other eye is dilating almost to the point where she can see light.
So far, 10 patients suffering from ONH have received the same stem-cell treatment in China, and doctors there claim that the vision of all 10 improved after the therapy.
At age 5, Rylea Barlett also received the stem-cell treatment. She, too, had been blind before.
Dr. Shalesh Kaushal, an eye specialist at the University of Florida, examined Bartlett, who is now 6, after she returned to the U.S.
"This child had essentially no light perception, and upon returning she's had a gradual improvement — so much so that at our exam it appeared that she had formed vision," he says. "That is to say that she could at least recognize large letters."
Kaushal concluded that the stem-cell therapy was the only clinical explanation for her improvement. Some infants with ONH gain more vision spontaneously over the first few years of life, but Barlett was already too old for that.
Kaushal is now evaluating other patients before and after the stem-cell treatment. But he is not recommending that patients go to China; he says much more research needs to be done.
"It's clearly a provocative result. ... If this is a real, reproducible observation or effect in other patients, one may consider it as a fundamental breakthrough," says Kaushal.
Reasons for Improvements Remain a Mystery
Dr. Sean Hu, the 40-year-old chairman of Beike Biotechnology, is a medical doctor-turned-entrepreneur with a doctorate in biochemistry from a Swedish university.
Less than three years ago, he set up Beike. Since then, 3,000 patients — most of them from China — have received Beike's stem-cell treatments for a wide range of conditions. He says 70 percent have seen improvements, but he admits he can't explain why.
"In the clinical areas, we know there are improvements. We don't know the mechanism behind it," Hu says.
That raises many concerns. Any improvement could be due to the placebo effect — or other factors besides the stem-cell therapy — and may not lead to longer-term functional gains. No rigorous, controlled clinical trials were carried out before the treatment was offered to patients. No research has yet been published in established peer-review journals overseas. And no one knows for sure what the possible risks might be.
But Hu isn't worried by the ethical implications of what he's doing.
"I can say I changed the life of these patients. Now they get their vision back. They went from completely blind, now they can see stuff. You think that's ethical or nonethical?" he asks.
Therapies Criticized as 'Extreme Nonsense'
Beike claims to treat a wide range of conditions with stem-cell therapy — from spinal-cord injuries to epilepsy to cerebral palsy to neurodegenerative disorders. But critics have their doubts.
Bruce Dobkin is director of the neurologic rehabilitation and research program at the University of California, Los Angles. In response to questions from NPR, he writes in an e-mail that "it is extreme nonsense to think that cells can be incorporated into the complex nervous system and do so much, when we cannot even get cells in mice and rats to do very much."
Chinese scientists are worried, too.
Dr. Naihe Jing is the deputy director of one of China's top stem-cell research labs and a member of the prestigious Chinese Academy of Sciences. He fears Beike could ruin the reputation of China's entire biotech industry.
"We think money is mainly behind this," he says, adding that he is concerned that one company's pursuit of profit will create a bad reputation for the whole country.
Providing Help, Providing Hope
Already, 600 foreigners have come to China and paid about $20,000 each for the stem-cell therapy, while even more Chinese patients are flocking for treatment.
The venture capital is flooding in, too. Hu, Beike's chairman, says he has raised about $15 million in funding, although NPR could not verify the claim. He admits making a calculated decision to go into stem-cell research: As he puts it, you have to choose the area with the best return.
"Obviously, [stem-cell research] is the most important area in biotech research in the future, because it's going to create a huge market, even bigger than the whole pharmaceutical industry. Stem-cell and regenerative medicine is the future of medicine," Hu says.
And parents continue to bring their children to Beike in the hopes of finding a cure for their ailments.
The results of Beike's experimental therapy may be uneven and unproven. Yet for patients and their families, hope is, perhaps, the most important commodity on sale in China — even if it costs tens of thousands of dollars.